The europe ophthalmic devices and drugs market size is expected to grow from USD 12.6 billion in 2025 to USD 13.52 billion in 2026 and is forecast to reach USD 19.26 billion by 2031 at 7.32% CAGR over 2026-2031. This report is Segmented by Product (Devices, Drugs), Disease (Glaucoma, Cataract, Age-Related Macular Degeneration, Diabetic Retinopathy, and More), End User (Hospitals, Specialty Clinics & ASCs, Retail Pharmacies & Optical Stores, Online Pharmacies), and Geography (Germany, United Kingdom, France, Italy, Spain, Rest of Europe). The Market Forecasts are Provided in Terms of Value (USD).
Meanwhile, new hydrogel implants and refillable ocular reservoirs target adherence gaps. Vision-care devices retain stable revenue streams via contact-lens material upgrades and blue-light-filter spectacles. Alcon’s 2025 Clareon PanOptix Pro IOL, boasting 94% light utilization, exemplifies engineering efforts that sustain price premiums. Across all modalities, companies intensify R&D to capture an ageing demographic seeking spectacle independence and rapid recovery.
Europe Ophthalmology Drug And Device Market Trends and Insights
Growing Prevalence of Chronic Eye Diseases
The incidence of age-related macular degeneration and diabetic retinopathy is climbing as Europe’s population ages, generating a durable demand base for both surgical and pharmaceutical interventions. Health systems are embedding ophthalmic screening into routine primary care, and German pilots using AI achieved 100% sensitivity for diabetic-retinopathy detection, catalyzing wider adoption. The economic burden of retinal disorders is estimated to hit EUR 99.8 billion by 2030, bolstering procurement budgets for advanced diagnostic equipment and sustained-release injectables.Expanding Geriatric Population Base
Individuals aged 65 years or older constitute Europe’s fastest-growing cohort and exhibit the highest prevalence of cataract, glaucoma, and AMD. National services are tackling surgical backlogs by contracting private providers, a model that raised UK cataract procedure volumes 40% over pre-pandemic levels. A larger elderly population simultaneously fuels premium IOL demand, reflecting patient preference for spectacle independence and rapid visual recovery.High Cost and Reimbursement Gaps for Premium Lenses/MIGS
Cataract surgery tariff disparities range from EUR 432.5 (USD 507.1) in Poland to EUR 3,411.96 (USD 4,001.21) in Portugal, causing uneven patient access to premium IOLs. Co-payment requirements depress uptake in social-insurance markets, while MIGS reimbursement remains procedure-specific, creating friction for innovators and clinicians alike. Germany’s 2025 abolition of fixed prices for visual aids illustrates the fluid reimbursement landscape.Other drivers and restraints analyzed in the detailed report include:
- Rapid Adoption of Minimally Invasive Glaucoma Surgery
- AI-Enabled Diagnostic Imaging & Remote Screening Rollout
- Stringent EU MDR Compliance Burden on SMEs
Segment Analysis
Surgical devices generated 46.12% of total 2025 revenue within the Europe ophthalmic devices and drugs market and continue to command premium pricing due to constant innovation. Alcon holds about 60% global share in presbyopia-correcting IOLs and has replicated similar penetration across major EU economies. Phaco platforms and femtosecond lasers secure attractive service contracts, while the fastest-expanding sub-segment is MIGS. The segment’s value proposition rises as bundled cataract-plus-MIGS procedures reduce overall care episodes.Meanwhile, new hydrogel implants and refillable ocular reservoirs target adherence gaps. Vision-care devices retain stable revenue streams via contact-lens material upgrades and blue-light-filter spectacles. Alcon’s 2025 Clareon PanOptix Pro IOL, boasting 94% light utilization, exemplifies engineering efforts that sustain price premiums. Across all modalities, companies intensify R&D to capture an ageing demographic seeking spectacle independence and rapid recovery.
Complete Report Scope:
- By Product
- Devices
- Surgical Devices
- Intra-ocular Lenses
- Ophthalmic Lasers
- Phacoemulsification Systems
- Other Surgical Devices
- Diagnostic Devices
- Optical Coherence Tomography Scanners
- Fundus Cameras
- Tonometers
- Other Diagnostic Devices
- Vision Care Devices
- Contact Lenses
- Spectacle Lenses
- Surgical Devices
- Drugs
- Glaucoma Drugs
- Retinal Disorder Drugs
- Dry-Eye Therapies
- Anti-Allergy / Anti-Inflammatory Drugs
- Anti-Infective Drugs
- Other Drugs
- Devices
- By Disease
- Glaucoma
- Cataract
- Age-related Macular Degeneration
- Diabetic Retinopathy
- Inflammatory Diseases
- Refractive Disorders
- Other Diseases
- By End User
- Hospitals
- Specialty Clinics & ASCs
- Retail Pharmacies & Optical Stores
- Online Pharmacies
- Geography
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
List of Companies Covered in this Report:
- Alcon
- Carl Zeiss
- Johnson & Johnson
- Bausch + Lomb Corp.
- EssilorLuxottica
- Novartis AG (incl. Sandoz & Sandoz Vision Care)
- Roche
- Pfizer
- Glaukos Corp.
- Santen Pharmaceuticals
- Staar Surgical Co.
- Topcon Corp.
- Nidek
- HAAG-Streit
- Ziemer Group
- Canon
- Hoya Corp. / Pentax Medical
- CooperVision Inc.
- Danaher
- Abbvie
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alcon AG
- Carl Zeiss Meditec AG
- Johnson & Johnson Vision
- Bausch + Lomb Corp.
- EssilorLuxottica SA
- Novartis AG (incl. Sandoz & Sandoz Vision Care)
- Roche Holding AG
- Pfizer Inc.
- Glaukos Corp.
- Santen Pharmaceutical Co. Ltd
- Staar Surgical Co.
- Topcon Corp.
- Nidek Co. Ltd
- Haag-Streit Group
- Ziemer Group AG
- Canon Medical Systems Corp.
- Hoya Corp. / Pentax Medical
- CooperVision Inc.
- Leica Microsystems GmbH
- Allergan (AbbVie)
